Chris Larson's Research Focus
Dr. Larson's scientific interests are unified by matching deep understanding of the etiology and pathophysiology of unmet medical needs to the predicted consequences of target biology modulation. His recent drug discovery research efforts focus on ameliorating the metabolic, energy balance, and ion activity and transport deficits in highly respiring tissues that underlie numerous poorly treated cardiovascular and metabolic diseases.
Chris Larson's Bio
Before joining SBP, Dr. Chris Larson spent six years at Takeda Pharmaceuticals, where he advanced numerous candidate drugs from research to global clinical development. His most recent position at Takeda was US head, and associate global head, of cardiovascular and metabolic diseases drug discovery, in which role he expanded the company’s US research enterprise into several new disease areas, introduced new drug and therapeutic modalities into the global cardiovascular and metabolic diseases portfolio, and pioneered an open innovation academic collaboration program and a Bioenergetics Center of Excellence at the research facilities in San Diego.